NEWS
2023.05.08
Release
ExaWizards and Kyoto University Develop Drug Safety Evaluation AI Learning from PMDA Evaluation Results 〜Promote more efficient reporting and evaluation of pharmaceutical products and reduce the number of cases requiring human evaluation〜
2023.05.01
Media
Listed in “100 Startups with a Track Record of Collaboration with Government” by the Ministry of Economy, Trade and Industry.
2023.04.28
Info
【Event】ExaWizards Care & Med Tech Forum 2023 〜Pioneering the next generation of medical healthcare and industrial innovation with AI〜
2023.04.28
Media
The Nikkei Business Daily reports on collaboration with PERSOL Holdings
2023.04.27
Release
ExaWizards Acquires a Patent for Anomaly Detection Technology Combining AI and Optics -AI that detects foreign matter contamination or state changes not detectable with the human eye by recognizing the test object and optimizes the wavelengths of lights applied to it-
2023.04.26
Release
Exawizards Has Begun Accepting Applications for Its New “exaBase Generative AI built with GPT-4” Service for Companies Interested in using ChatGPT ~¥900/Month Basic Fee, Security and Compliance Management Features Come Standard ~
2023.04.24
Release
ExaWizards Establishes Fukuoka Office as its Fifth Regional Hub in Japan -Aiming to expand its business with a focus mainly on the finance sector in the Kyushu/Chugoku regions-
2023.04.22
Release
ExaWizards and MDV Sign a MOU on Multimodal AI-Enabled Data-Driven Business 〜Utilising the country’s largest medical big data held by MDV, Contributing to the development of new services for the field of rare diseases〜
2023.04.20
Media
Nikkei Newspaper features comments from advisor Professor Osborn
2023.04.18
Release